Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan breast cancer research network-07 trial

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 185-189

  Yamamoto, Daigo ^a,c   Iwase, Satoru ^b   Tsubota, Yu ^a   Sueoka, Noriko ^a   Yamamoto, Chizuko ^c   Kitamura, Kaoru ^d   Odagiri, Hiroki ^e   Nagumo, Yoshinori ^f  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c Seiko Hospital   (Japan)

^d Breast Unit   (Japan)

^e HIROSAKI NATIONAL HOSPITAL   (Japan)

^f Nagumo Clinic   (Japan)

Author keywords

Bevacizumab; Brain; Metastatic breast cancer

Indexed keywords

BEVACIZUMAB; PACLITAXEL;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIPLOPIA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EXTRAOCULAR MUSCLE; FEMALE; HUMAN; HYPERTENSION; METASTASIS; NEUROPATHY; OUTCOME ASSESSMENT; PROTEINURIA; PTOSIS; TREATMENT DURATION;

EID: 84873929747     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S36515     Document Type: Article

References (22)

1. Shin HR, Boniol M, Joubert C, et al. Secular trends in breast cancer mortality in five East Asian populations: Hong Kong, Japan, Korea, Singapore and Taiwan. Cancer Sci. 2010;101:1141-1246.
2. Perez EA. Current management of metastatic breast cancer. Semin Oncol. 1999;26:1-10.
3. Kawaguchi T, Iwase S, Takeuchi H, et al. Chemotherapy with low dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report. Cases J. 2009;24:9081.
4. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339: 974-984.
5. Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012;4:CD003869.
6. Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first line therapy for HER2-negative metastatic breast cancer. Drugs. 2011;71:2213-2229.
7. Gordon MS, Margolin K, Talpaz M. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843-850.
8. Friedman HS, Prados MD, Wen P Y, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
9. Agha CA, Ibrahim S, Hassan A, Elias DA, Fathallah-Shaykh HM. Bevacizumab is active as a single agent against recurrent malignant gliomas. Anticancer Res. 2010;30:609-611.
10. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non small cell lung cancer and brain metastases. J Clin Oncol. 2009;27:5255-5261.
11. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr U P. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16:269-278.
12. Labidi SI, Bachelot T, Ray-Coquard I, et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer. 2009;9:118-121.
13. Bhaskara A, Eng C. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer. 2008;7:65-68.
14. Yamamoto D, Iwase S, Yoshida H, et al. Efficacy of meloxicam in combination with preoperative chemotherapy for breast cancer Japan Breast Cancer Research Network (JBCRN) 02-1 Trial. Anticancer Res. 2011;31:3567-3572.
15. De Boer AG, Gaillard PJ. Strategies to improve drug delivery across the blood brain barrier. Clin Pharmacokinet. 2007;46:553-576.
16. Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
17. Ay I, Francis JW, Brown RH. VEGF increases blood brain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno associated virus in ALS mice. Brain Res. 2008;1234:198-205.
18. Zadeh G, Guha A. Molecular regulators of angiogenesis in the developing nervous system and adult brain tumors. Int J Oncol. 2003;23: 557-565.
19. Gerstner ER, Fine RL. Increased permeability of the blood brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007;25:2306-2312.
20. Dietrich WD, Busto R, Halley M. The importance of brain temperature in alterations of the blood brain barrier following cerebral ischemia. J Neuropathol Exp Neurol. 1990;49:486-497.
21. ClinicalTrials.gov. Bevacizumab in reducing CNS side effects in patients who have undergone radiation therapy to the brain for primary brain tumor, Meningioma, or head and neck cancer. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00492089. Accessed August 27, 2012.
22. ClinicalTrials.gov. A study of bevacizumab in combination with firstor second-line therapy in subjects with brain metastases due to non squamous NSCLC (PASSPORT). Available at: http://clinicaltrials. gov/ct2/results?term=NCT00312728. Accessed August 27, 2012.